There are 412 resources available
Key learnings/closing remarks
Presenter: Natasha Leighl
Session: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC
Resources:
Webcast
Evolving role of TTFields therapy in NSCLC
Presenter: Joachim Aerts
Session: Novocure GmbH - The evolving role of TTFields therapy in solid tumors
Resources:
Webcast
IO and chemotherapy before or after surgery?
Presenter: Luis Paz-Ares
Session: Managing stage III NSCLC in the era of IO
Resources:
Slides
Webcast
A surgeon's perspective
Presenter: Gaetano Rocco
Session: Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC?
Resources:
Slides
Webcast
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
Presenter: Dongsheng Yue
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast